Press coverage about Revance Therapeutics (NASDAQ:RVNC) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revance Therapeutics earned a news sentiment score of 0.12 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 45.9012825613874 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:
- Revance Therapeutics Inc (RVNC) CEO Sells $204,141.28 in Stock (americanbankingnews.com)
- Phyllis Gardner Sells 5,333 Shares of Revance Therapeutics Inc (RVNC) Stock (americanbankingnews.com)
- Revance Therapeutics, Inc. (RVNC) finishes with 1.19% while stock price is worth at $34.10 – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Revance Therapeutics, Inc. (RVNC) Punches One Year New High – The Stocks News (press release) (thestocksnews.com)
- The CFO, CBO & Secretary of Revance Therapeutics (NASDAQ: RVNC) is Buying Shares – Analyst Ratings (analystratings.com)
Revance Therapeutics (RVNC) opened at $31.00 on Friday. Revance Therapeutics has a fifty-two week low of $18.42 and a fifty-two week high of $37.45.
Revance Therapeutics (NASDAQ:RVNC) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). The firm had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.09 million. Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. Revance Therapeutics’s revenue was down 50.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.95) earnings per share. analysts anticipate that Revance Therapeutics will post -3.64 EPS for the current year.
RVNC has been the topic of a number of recent analyst reports. Barclays initiated coverage on shares of Revance Therapeutics in a research note on Monday, November 27th. They set an “overweight” rating and a $31.00 price objective on the stock. Cantor Fitzgerald set a $50.00 price objective on shares of Revance Therapeutics and gave the company a “buy” rating in a research note on Wednesday, November 29th. ValuEngine cut shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 4th. Piper Jaffray Companies lifted their price objective on shares of Revance Therapeutics from $28.00 to $51.00 and gave the company an “overweight” rating in a research note on Tuesday, December 5th. Finally, Guggenheim initiated coverage on shares of Revance Therapeutics in a research note on Tuesday, December 5th. They set a “buy” rating and a $42.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $45.45.
In related news, CEO L Daniel Browne sold 6,452 shares of Revance Therapeutics stock in a transaction dated Friday, March 16th. The stock was sold at an average price of $31.64, for a total transaction of $204,141.28. Following the transaction, the chief executive officer now directly owns 130,208 shares of the company’s stock, valued at $4,119,781.12. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Lauren P. Silvernail sold 25,867 shares of Revance Therapeutics stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.50, for a total value of $892,411.50. Following the transaction, the chief financial officer now directly owns 98,821 shares in the company, valued at $3,409,324.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 94,935 shares of company stock worth $3,077,100. 18.86% of the stock is owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: This news story was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/03/17/revance-therapeutics-rvnc-receiving-somewhat-positive-press-coverage-report-finds.html.
Revance Therapeutics Company Profile
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.